An ongoing dialogue on HIV/AIDS, infectious diseases,
April 14th, 2010
Maraviroc Rarely Used for Treatment-Naive Patients
Over in Journal of Infectious Diseases, the MERIT study was recently published (with Chuck Hicks’ Journal Watch summary here), demonstrating that maraviroc is non-inferior to efavirenz — provided that the enhanced-sensitivity tropism test is used to select appropriate candidates.
(The MERIT study began in 2004-5. Don’t think I’ll ever forget that, since the investigator meeting overlapped with this memorable series. Notable event pictured.)
Despite these favorable results from the trial — and the FDA approval of the drug for treatment-naive patients — I agree with Chuck that mariviroc will get little use in this population, if only because the “preferred” alternatives (efavirenz, atazanavir/r, darunavir/r, raltegravir) are so incredibly good.
Our reader poll (right side of page) confirms how rarely the drug is prescribed as initial therapy. I suspect that some of the respondents who said they have given the drug to these patients did so within a clinical trial, which would make the response even lower.
Will maraviroc — or another CCR5 antagonist — ever have widespread use in HIV treatment?
Call me an optimist, but I envision that these drugs will be part of an aggressive eradication strategy, somehow based on the remarkable case of “cure” following bone marrow transplantation from a CCR5-negative donor.
Hey, I can dream can’t I? Red Sox fans certainly did in 2004.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Shock Not Advised April 25, 2026A physician offers to help in a medical emergency on a transatlantic flight. Though she faces limits of bureaucracy, equipment, and ultimately biology, she discovers her physicianhood is inescapable.
- Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock April 24, 2026In children with septic shock, no significant difference was seen in the incidence of death, new renal-replacement therapy, or persistent kidney dysfunction with balanced fluid as compared with 0.9% saline for fluid resuscitation.
- Tuberculosis Cases and Deaths Averted by PEPFAR April 23, 2026Tuberculosis remains a leading cause of death worldwide among persons with HIV. In this report, the effect of the PEPFAR program on incident cases of tuberculosis and related deaths is presented.
- Case 12-2026: An 86-Year-Old Woman with Anorexia, Weight Loss, and Liver Lesions April 23, 2026An 86-year-old woman with a history of diabetes and breast cancer was admitted to the hospital with anorexia and weight loss. Imaging revealed multifocal liver lesions. A diagnosis was made.
- Same Pill, Different Impact — Reassessing the Efficacy of Nirmatrelvir–Ritonavir April 23, 2026The first cases of Covid-19 were reported at the end of 2019, and from January 20, 2020, to May 5, 2023, Covid-19 was considered to be a public health emergency of international concern. The total number of cases worldwide exceeded 1 million by early April 2020. In the United States,...
- Shock Not Advised April 25, 2026